Skip to Main content Skip to Navigation
Journal articles

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Abstract : Background: Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumorspecific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC.
Document type :
Journal articles
Complete list of metadata
Contributor : Anne Poupon <>
Submitted on : Friday, December 4, 2020 - 9:35:33 AM
Last modification on : Monday, July 19, 2021 - 4:18:11 PM
Long-term archiving on: : Friday, March 5, 2021 - 6:21:25 PM


Publisher files allowed on an open archive



Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay Alcaraz, Pascal Roger, et al.. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. Journal for Immunotherapy of Cancer, BMJ Publishing Group 2019, 7, ⟨10.1186/s40425-019-0498-z⟩. ⟨hal-03039856⟩



Record views


Files downloads